Peter Ball

Summary

Publications

  1. ncbi request reprint Comparative tolerability of the newer fluoroquinolone antibacterials
    P Ball
    School of Biomedical Sciences, University of St Andrews, Fife, Scotland
    Drug Saf 21:407-21. 1999
  2. ncbi request reprint The clinical development and launch of amoxicillin/clavulanate for the treatment of a range of community-acquired infections
    Peter Ball
    School of Biomedical Sciences, St Andrews University, St Andrews, Fife, UK
    Int J Antimicrob Agents 30:S113-7. 2007
  3. ncbi request reprint A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context
    P Ball
    School of Biomedical Sciences, St Andrews University, St Andrews, Fife, 6 Gilchrist Row, Scotland KY16 8XU, UK
    Int J Antimicrob Agents 23:421-9. 2004
  4. ncbi request reprint Adverse drug reactions: implications for the development of fluoroquinolones
    Peter Ball
    School of Biomedical Sciences, University of St Andrews, 6 Gilchrist Row, St Andrews, Fife KY16 8XU, Scotland, UK
    J Antimicrob Chemother 51:21-7. 2003
  5. ncbi request reprint Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence
    P Ball
    School of Biomedical Sciences, St Andrews University, St Andrews, Fife, UK
    J Antimicrob Chemother 49:31-40. 2002
  6. ncbi request reprint Future of the quinolones
    P Ball
    School of Biomedical Sciences, University of St Andrews, St Andrews, Fife, Scotland
    Semin Respir Infect 16:215-24. 2001
  7. ncbi request reprint Conclusions: the future of antimicrobial therapy - Augmentin and beyond
    Peter Ball
    School of Biomedical Sciences, St Andrews University, St Andrews, Fife, UK
    Int J Antimicrob Agents 30:S139-41. 2007
  8. ncbi request reprint Quinolone generations: natural history or natural selection?
    P Ball
    University of St Andrews, Fife, Scotland, UK
    J Antimicrob Chemother 46:17-24. 2000
  9. ncbi request reprint New antibiotics for community-acquired lower respiratory tract infections: improved activity at a cost?
    P Ball
    Department of Biomedical Sciences, University of St Andrews, Fife, Scotland, St Andrews, UK
    Int J Antimicrob Agents 16:263-72. 2000
  10. ncbi request reprint Safety of the new fluoroquinolones compared with ciprofloxacin
    P Ball
    School of Biomedical Sciences, University of St Andrews, Fife, Scotland, UK
    J Chemother 12:8-11. 2000

Detail Information

Publications17

  1. ncbi request reprint Comparative tolerability of the newer fluoroquinolone antibacterials
    P Ball
    School of Biomedical Sciences, University of St Andrews, Fife, Scotland
    Drug Saf 21:407-21. 1999
    ..Data from over 1700 children in the UK failed to disclose arthropathy and extensive paediatric use of norfloxacin in Japan and ciprofloxacin in developing countries has been free of articular effects...
  2. ncbi request reprint The clinical development and launch of amoxicillin/clavulanate for the treatment of a range of community-acquired infections
    Peter Ball
    School of Biomedical Sciences, St Andrews University, St Andrews, Fife, UK
    Int J Antimicrob Agents 30:S113-7. 2007
    ....
  3. ncbi request reprint A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context
    P Ball
    School of Biomedical Sciences, St Andrews University, St Andrews, Fife, 6 Gilchrist Row, Scotland KY16 8XU, UK
    Int J Antimicrob Agents 23:421-9. 2004
    ..In conclusion, gemifloxacin 320 mg once daily demonstrated a favourable safety and tolerability profile similar to that of comparator antibiotics, including other quinolones...
  4. ncbi request reprint Adverse drug reactions: implications for the development of fluoroquinolones
    Peter Ball
    School of Biomedical Sciences, University of St Andrews, 6 Gilchrist Row, St Andrews, Fife KY16 8XU, Scotland, UK
    J Antimicrob Chemother 51:21-7. 2003
    ....
  5. ncbi request reprint Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence
    P Ball
    School of Biomedical Sciences, St Andrews University, St Andrews, Fife, UK
    J Antimicrob Chemother 49:31-40. 2002
    ..Application of these principles should positively benefit therapeutic outcomes, resistance avoidance and management costs and will more accurately guide antibiotic choices by both individuals and formulary/guideline committees...
  6. ncbi request reprint Future of the quinolones
    P Ball
    School of Biomedical Sciences, University of St Andrews, St Andrews, Fife, Scotland
    Semin Respir Infect 16:215-24. 2001
    ..These agents are now licensed in many countries, including the United States, and add a further, broad-based respiratory dimension to the future of the class...
  7. ncbi request reprint Conclusions: the future of antimicrobial therapy - Augmentin and beyond
    Peter Ball
    School of Biomedical Sciences, St Andrews University, St Andrews, Fife, UK
    Int J Antimicrob Agents 30:S139-41. 2007
    ..The development of new dosages and formulations of amoxicillin/clavulanate allows this agent to continue to fill the important role in therapy which it has occupied, and continues to occupy, 25 years after it was launched...
  8. ncbi request reprint Quinolone generations: natural history or natural selection?
    P Ball
    University of St Andrews, Fife, Scotland, UK
    J Antimicrob Chemother 46:17-24. 2000
    ..Preliminary data indicate that gemifloxacin should prove to be an important addition to the fluoroquinolone class. Further clinical trial data are awaited with interest...
  9. ncbi request reprint New antibiotics for community-acquired lower respiratory tract infections: improved activity at a cost?
    P Ball
    Department of Biomedical Sciences, University of St Andrews, Fife, Scotland, St Andrews, UK
    Int J Antimicrob Agents 16:263-72. 2000
    ..All quinolones so far tested appear to prolong the QTc interval, but only sparfloxacin and grepafloxacin caused clinical effects. Nevertheless, caution is required until this effect is fully investigated...
  10. ncbi request reprint Safety of the new fluoroquinolones compared with ciprofloxacin
    P Ball
    School of Biomedical Sciences, University of St Andrews, Fife, Scotland, UK
    J Chemother 12:8-11. 2000
    ..Hospitalised patients are likely to be receiving multiple-drug therapy, but drug interactions are avoidable. The interactions of specific fluoroquinolones should be checked prior to prescription...
  11. ncbi request reprint Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomised, double-blind comparison with trovafloxacin
    P Ball
    University of St Andrews, Fife, Scotland
    J Chemother 13:288-98. 2001
    ..The clinical and bacteriological efficacy of a once-daily 5-day course of gemifloxacin is at least as good as that of a similar regimen of trovafloxacin in the treatment of acute exacerbations of chronic bronchitis...
  12. ncbi request reprint Basic principles for compounding all-in-one parenteral nutrition admixtures
    G Hardy
    School of Pharmacy, University of Otago, Dunedin, New Zealand
    Curr Opin Clin Nutr Metab Care 1:291-6. 1998
    ....
  13. ncbi request reprint Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections
    P Ball
    Saint Andrews, Fife, Scotland KY16 8XU, UK
    Int J Antimicrob Agents 18:19-27. 2001
    ..8, 86.3). Gemifloxacin was well tolerated with a low incidence of adverse events. Gemifloxacin treatment resulted in high clinical and bacteriological success rates and is a well-tolerated therapy for the treatment of LRTIs...
  14. ncbi request reprint Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies
    Peter Ball
    University of St Andrews, Fife, Scotland
    Clin Ther 26:940-50. 2004
    ..Moxifloxacin is a broad-spectrum, advanced-generation fluoroquinolone that has potent activity against respiratory tract infections in adults in both oral and IV formulations...
  15. ncbi request reprint A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes
    Robert Wilson
    Royal Brompton Hospital, London, England
    Clin Ther 24:639-52. 2002
    ..Gemifloxacin is an enhanced-affinity quinolone with potent activity against lower respiratory tract pathogens...
  16. ncbi request reprint Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical effic
    Hartmut Lode
    Department of Chest and Infectious Diseases, Hospital Heckeshorn, Akademisches Lehrkrankenhaus, Free University Berlin, Berlin, Germany
    Clin Ther 24:1915-36. 2002
    ....
  17. ncbi request reprint Meeting report: Fourth Forum on Respiratory Tract Infections, Sitges, Spain, 8 11 February 2007
    Glenn S Tillotson
    Replidyne Inc, Milford, CT, USA
    J Antimicrob Chemother 60:464-9. 2007
    ..The 2007 Forum was chaired by Professors Antoni Torres Marti, Giuliana Gialdroni Grassi and Dr Peter Ball and received academic endorsement from the British Society for Antimicrobial Chemotherapy (BSAC), Italian ..